Clinical validation for the aldosterone-to-renin ratio and aldosterone suppression testing using simultaneous fully automated chemiluminescence immunoassays
- 1 December 2015
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal Of Hypertension
- Vol. 33 (12), 2500-2511
- https://doi.org/10.1097/hjh.0000000000000727
Abstract
As larger numbers of hypertensive patients are screened for primary aldosteronism with the aldosterone-to-renin ratio (ARR), automated analyzers present a practical solution for many laboratories. We report the method-specific ARR cutoff determined with direct, automated chemiluminescence immunoassays allowing the simultaneous measurement of plasma aldosterone concentrations (PACs) and plasma renin concentrations (PRCs). Method comparisons to commonly employed assays and tandem mass spectrometry were undertaken. Patients were previously diagnosed based on the local ARR cutoff of 1.2 (ng/dl)/(μIU/ml) in samples collected in upright seated position. Lack of aldosterone suppression in response to salt load to less than 5 ng/dl confirmed primary aldosteronism. For the new assays, the optimal ARR cutoff was established in 152 patients with essential hypertension, 93 with primary aldosteronism and 147 normotensive patients. Aldosterone suppression was assessed in 73 essential hypertensive and 46 primary aldosteronism patients. PAC and PRC were significantly correlated to values determined with currently available methods (P < 0.001). In patients with primary aldosteronism, patients with essential hypertension and controls, mean (95% confidence interval) PAC was 28.4 (25.4-31.8), 6.4 (5.9-6.9) and 6.2 (5.6-6.9) ng/dl, respectively. In the same groups, PRC was 6.6 (5.6-7.7), 12.9 (11.2-14.8) and 26.5 (22.2-31.5) μIU/ml. An ARR cutoff of 1.12 provided 98.9% sensitivity and 78.9% specificity. Employing the new assay aldosterone suppression confirmed the diagnosis of primary aldosteronism and essential hypertension using the cutoff of 5 ng/dl. Our data demonstrate that the new assays present a convenient alternative for the measurement of PAC and PRC on a single automated analyzer. Availability of these simultaneous assays should facilitate screening and diagnosis of primary aldosteronism.Keywords
This publication has 53 references indexed in Scilit:
- Hyperaldosteronism as a Common Cause of Resistant HypertensionAnnual Review of Medicine, 2013
- Supported liquid extraction offers improved sample preparation for aldosterone analysis by liquid chromatography tandem mass spectrometryJournal of Clinical Pathology, 2012
- Spontaneous remission of idiopathic aldosteronism after long‐term treatment with spironolactone: results from the German Conn’s RegistryClinical Endocrinology, 2011
- Activity Assays and Immunoassays for Plasma Renin and Prorenin: Information Provided and Precautions Necessary for Accurate MeasurementClinical Chemistry, 2009
- Multimarker Approach to Evaluate Correlates of Vascular StiffnessCirculation, 2009
- Prospective evaluation of the saline infusion test for excluding primary aldosteronism due to aldosterone-producing adenomaJournal Of Hypertension, 2007
- Clinical and Genetic Correlates of Aldosterone-to-Renin Ratio and Relations to Blood Pressure in a Community SampleHypertension, 2007
- Plasma renin and aldosterone measurements in low renin hypertensive statesTrends in Endocrinology & Metabolism, 2005
- Immunoradiometric versus enzymatic renin assayJournal of Hypertension, 1995
- Determination of steroid hormones by the use of isotope dilution-mass spectrometry: A definitive method in clinical chemistryJournal of Steroid Biochemistry, 1979